Enhancement of immobility in mouse forced swimming test by treatment with human interferon

European Journal of Pharmacology

Volumn 356, Issue 1, 1998, Pages 1-7

  Makino, Mitsuhiro ^a   Kitano, Yutaka ^a   Hirohashi, Masaaki ^a   Takasuna, Kiyoshi ^a  

^a Drug Safety Research Laboratory   (Japan)

Author keywords

Antidepressant; Depression; Forced swimming test; Interferon

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BETA INTERFERON; GAMMA INTERFERON; HUMAN INTERFERON; IMIPRAMINE; INTERFERON; MIANSERIN; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; FORCED SWIMMING TEST; IMMOBILIZATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMIPRAMINE; INJECTIONS, INTRAVENOUS; INTERFERON-ALPHA; INTERFERONS; MALE; MICE; MOTOR ACTIVITY; SWIMMING; TIME FACTORS;

EID: 0032575617     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00474-9     Document Type: Article

References (35)

1. Adams F., Quesada J.R., Gutterman J.U. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. JAMA. 252:1984;938-941.
2. Adams F., Fernandez F., Mavligit G. Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities. J. Neurooncol. 6:1988;355-359.
3. Arenzana-Seisdedos F., Virelizier J.L. Interferons as macrophage-activating factors II. Enhanced secretion of interleukin-1 by lipopolysaccharide-stimulated human monocytes. Eur. J. Pharmacol. 13:1983;437-440.
4. Birmanns B., Saphier D., Abramsky O. α-Interferon modifies cortical EEG activity: dose-dependence and antagonism by naloxone. J. Neurol. Sci. 100:1990;22-26.
5. Blalock J.E., Smith E.M. Human leukocyte interferon: structural and biological relatedness to adrenocorticotropic hormone and endorphins. Proc. Natl. Acad. Sci. USA. 77:1980;5972-5974.
6. Blalock J.E., Stanton J.D. Common pathways of interferon and hormonal action. Nature. 283:1980;406-408.
7. Blalock J.E., Smith E.M. Human leukocyte interferon (Huinterferon-α): potent endorphin-like opioid activity. Biochem. Biophys. Res. Commun. 101:1981;472-478.
8. Bocci V. Central nervous system toxicity of interferons and other cytokines. J. Biol. Regul. Homeostat. Agents. 2:1988;107-118.
9. Bocci V. Pharmacology and side-effects of interferons. Antiviral Res. 24:1994;111-119.
10. Borsini F., Meli A. Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology. 94:1988;147-160.
11. Dafny N., Lee J.R., Dougherty P.M. Immune response products alter CNS activity: interferon modulates central opioid functions. J. Neurosci. Res. 19:1988;130-139.
12. Dunn A.L., Crnic L.S. Repeated injections of interferon-α A/D in Balb/c mice: behavioral effects. Brain, Behavior, and Immunity. 7:1993;104-111.
13. Gisslinger H., Svoboda T., Clodi M., Gilly B., Ludwig H. Interferon-α stimulates the hypothalamic-pituitary-adrenal axis in vivo and in vitro. Neuroendocrinology. 57:1993;489-495.
14. Hoofnagle J.H., Mullen K.D., Jones D.B., Rustigi V., Di Bisceglie A., Peters M., Waggoner J.G., Park Y., Jones E.A. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. N. Engl. J. Med. 315:1986;1575-1578.
15. Iivanainen M., Laaksonen R., Niemi M.L., Färkkilä M., Bergström L., Mattson K., Niiranen A., Cantell K. Memory and psychomotor impairment following high-dose interferon treatment in amyotrophic lateral sclerosis. Acta Neurol. Scand. 72:1985;475-480.
16. Krueger J.M., Dinarello C.A., Shoham S., Davenne D., Walter J., Kubillus S. Interferon alpha-2 enhances slow-wave sleep in rabbits. Int. J. Immunopharmacol. 9:1987;23-30.
17. Langer J.A., Pestka S. Interferon receptors. Immunol. Today. 9:1988;393-400.
18. Mattson K., Niiranen A., Iivanainen M., Färkkilä M., Bergström L., Holsti L.R., Kauppinen H.L., Cantell K. Neurotoxicity of interferon. Cancer Treatment Report. 67:1983;958-961.
19. Menzies R.A., Patel R., Hall N.R.S., O'Grady M.P., Rier S.E. Human recombinant interferon alpha inhibits naloxone binding to rat brain membranes. Life Sci. 50:1992;227-232.
20. Meyers C.A., Scheibel R.S., Forman A.D. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology. 41:1991;672-676.
21. Nolten W.E., Goldstein D., Lindstrom M., Mckenna M.V., Carlson I.H., Trump D.L., Schiller J., Borden E.C., Ehrlich E.N. Effects of cytokines on the pituitary-adrenal axis in cancer patients. J. Interferon Res. 13:1993;349-357.
22. Otubo T., Miyaoka H., Kamijima K., Onuki M., Ishii M., Mitamura K. Depression drug interferon therapy in chronic hepatitis C patients - a prospective study. Psychiat. Neurol. Jpn. 99:1997;101-127.
23. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature. 266:1977;730-732.
24. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioral despair in rats: a new model sensitive to antidepressant treatments. Eur. J. Pharmacol. 47:1978;379-391.
25. Prasad S., Waters B., Hill P.B., Portera F.A., Riely C.A. Psychiatric side effects of interferon alpha-2b in patients treated for hepatitis C. Abstract Clin. Res. 40:1992;840A.
26. Quesada J.R., Talpaz M., Rios A., Kurzrock R., Gutterman J.U. Clinical toxicity of interferon in cancer patients: a review. J. Clin. Oncol. 4:1986;234-243.
27. Renault P.F., Hoofnagle J.H., Park Y., Mullen K.D., Peters M., Jones D.B., Rustgi V., Jones E.A. Psychiatric complications of long-term interferon alpha therapy. Arch. Intern. Med. 147:1987;1577-1580.
28. Rohatiner A.Z.S., Prior P.F., Burton A.C., Smith A.T., Balkwill F.R., Lister T.A. Central nervous system toxicity of interferon. Br. J. Cancer. 47:1983;419-422.
29. Sen G.C., Lengyel P. The interferon system. J. Biol. Chem. 267:1992;5017-5020.
30. Shimazoe T., Shibata S., Ueki S. A new forced swimming test for the evaluation of antidepressants in rats by recording vibration of a water tank. J. Pharmacobio-Dyn. 11:1987;639-643.
31. Smedley H., Katrak M., Sikora K., Wheeler T. Neurological effects of recombinant human interferon. Br. Med. J. 286:1983;262-264.
32. Suter C.C., Westmoreland B.F., Sharbrough F.W., Hermann R.C. Electroencephalographic abnormalities in interferon encephalopathy: a preliminary report. Mayo Clin. Proc. 59:1984;847-850.
33. Takagi S. Psychiatric manifestations of interferon therapy. Seishin Igaku (Clinical Psychiatry). 37:1995;344-358.
34. Vial T., Descotes J. Clinical toxicity of the interferons. Drug Safety. 10:1994;115-150.
35. Willner P. The validity of animal models of depression. Psychopharm. 83:1984;1-16.